Goodwin Procter LLP advised Mirati Therapeutics, Inc. on the deal. Mirati Therapeutics, Inc. (NASDAQ: MRTX) announced its collaboration and license agreement with Zai Lab Limited (NASDAQ:...
Mirati Therapeutics’ Collaboration and License agreement with Zai Lab Limited
BridgeBio Pharma’s $2.45 Billion Collaboration and Licensing Agreement with Helsinn Group
Goodwin Procter LLP advised BridgeBio Pharma, Inc. on the deal. BridgeBio Pharma, Inc. (Nasdaq: BBIO) and its affiliate QED Therapeutics, Inc. announced a global collaboration and licensing...